The "Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The 'Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 - 2030' report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems. It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain.
Targeting the delivery of drugs directly into the lungs is deemed to be the most effective way to ensure optimal therapeutic benefits while treating pulmonary disorders. In addition, this route of administration has also been shown to be effective for drugs intended to treat a variety of other conditions, including various metabolic (460+ million adults estimated to be living with diabetes) , hormonal, autoimmune, infectious diseases/disorders and mental health conditions (260 million individuals estimated to be suffering from depression and around 50 million have epilepsy, worldwide).
As a result, innovators in the pharmaceutical industry are engaged in efforts to develop the means to formulate and administer pharmacological interventions via inhalation and/or the intranasal route. Since 2019, the FDA has approved multiple inhaled and intranasal drug products, namely TOSYMRAT (migraine), NUMBRINOT (local anesthetic), GIMOTIT (diabetic gastroparesis), VALTOCO (epilepsy), NAYZILAM (epilepsy), DUAKLIR PRESSAIR (COPD), PROAIR DIGIHALERT (asthma and COPD), AIRDUO DIGIHALERT (asthma), SPRAVATO (depression).
Presently, several players are attempting to develop inhalable versions of different classes of drugs. In such endeavors, reformulating complex therapeutic molecules (such as biologics), novel drug classes (such as nanoparticle based medicine) and those intended for systemic delivery, present unique challenges. Further, the inhaled route of delivery itself has always been associated with several challenges, mostly related to ensuring the drug to its intended target.
These concerns are further compounded by multiple physiological barriers, such as mucus hypersecretion/thickening, narrowing/collapse of airways, fibrosis and poor blood circulation. In order to navigate through the aforementioned challenges, innovators prefer to rely on specialty service providers with expertise in inhaled and intranasal nasal medicine.
Such players, given their experience and niche expertise, enable innovator companies to not only expedite product development and production timelines, but also offer cost saving opportunities as well. Further, such service providers generally have the necessary infrastructure to scale-up operations in order to meet the evolving needs of a business across different stages of product development.
Given the anticipated growth in demand for inhaled and intranasal drug products, the specialty contract services market catering to this segment of the pharmaceutical industry, is anticipated to witness substantial growth in the coming years.
Key Questions Answered
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Inhaled and Intranasal Therapy
3.3. Types of Inhalable and Intranasal Drug Formulations
3.4. Types of Inhalable and Intranasal Drug Delivery Systems Formulations
3.4.1. Pressurized Metered Dose Inhalers
3.4.2. Dry Powder Inhalers
3.4.3. Nebulizers
3.4.4. Metered Spray Pumps / Intranasal Sprays
3.4.5. Aqueous Droplet Inhalers
3.5. Assessment of Quality and Performance During Inhalable and Intranasal Drug Development
3.6. Regulatory Landscape
3.7. Approved Inhaled and Intranasal Therapeutics Available in Developed Markets (the US and UK)
3.8. Importance of Outsourcing Inhaled and v Product Development Operations
3.9. Future Perspectives
4. INHALED AND INTRANASAL DRUG PRODUCT SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Inhaled and Intranasal Drug Product Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size
4.2.4. Analysis by Type of Service Provider
4.2.5. Analysis by Company Size and Type of Service Provider
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Location of Headquarters
4.2.8. Heat Map: Analysis by Company Size and Location of Headquarters
4.2.9. World Map: Analysis by Inhaled and Intranasal Drug Product Manufacturing Facilities
4.2.10. Analysis by Type of Drug Molecule
4.2.11. Analysis by Type of Inhaled and Intranasal Drug Product Related Primary Service(s) Offered
4.2.12. Analysis by Type of Inhaled and Intranasal Drug Product Related Secondary Service(s) Offered
4.2.13. Analysis by Type of Formulation
4.2.14. Analysis by Type of Dosage Form
4.2.15. Analysis by Route of Administration
4.2.16. Information on Production Capacity
5. INHALED AND INTRANASAL DRUG DELIVERY SYSTEM MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Inhaled and Intranasal Drug Delivery System Manufacturing Service Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Logo Landscape: Analysis by Year of Establishment and Company Size
5.2.4. Analysis by Scale of Operation
5.2.5. Analysis by Location of Headquarters
5.2.6. Analysis by Location of Inhaled and Intranasal Drug Delivery System Manufacturing Facilities
5.2.7. Analysis by Type of Inhaled and Intranasal Drug Delivery System Manufacturing Service(s) Offered
5.2.8. Analysis by Type of Formulation
5.2.10. Analysis by Type of Drug Delivery Systems
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. Inhaled and Intranasal Drug Product Contract Manufacturing Service Providers
6.4. Inhaled and Intranasal Drug Product Contract Research Service Providers
6.5. Inhaled and Intranasal Drug Product Contract Research and Manufacturing Service Providers
7. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Capsugel
7.2.1. Recent Developments and Future Outlook
7.3. Catalent
7.4. DPT Laboratories (A Mylan Company)
7.5. Kindeva Drug Delivery (Formerly 3M Drug Delivery Systems)
8. INHALED AND INTRANASAL CONTRACT MANUFACTURING SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC
8.1. Chapter Overview
8.2. Beximco Pharmaceuticals
8.2.1. Recent Developments and Future Outlook
8.3. Colep
8.4. Hovione
8.5. Orion
8.6. Quotient Sciences
8.7. Recipharm
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Inhaled and Intranasal Contract Research and Manufacturing Service Providers:
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Scale of Operation
9.3.4. Analysis by Type of Inhaled and Intranasal Drug Product Related Service(s) Offered
9.3.5. Analysis by Type of Formulation
9.3.6. Analysis by Type of Drug Delivery Systems Used
9.3.7. Most Active Players: Analysis by Number of Partnerships
10. MAKE VERSUS BUY DECISION MAKING
10.1. Chapter Overview
10.2. Assumptions and Parameter Definitions
10.3. Concluding Remarks
11. DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Global Demand for Inhaled and Intranasal Drug Delivery Systems, 2020-2030
11.3.1. Analysis by Route of Administration
11.3.2. Analysis by Type of Drug Delivery Systems Used
11.3.3. Analysis by Geographical Location
12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Inhaled and Intranasal Drug Product Contract Manufacturing Market, 2020-2030
12.4. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Inhalable Formulations, 2020-2030
12.5. Inhaled and Intranasal Drug Product Contract Manufacturing Market for Nasal Formulations, 2020-2030
12.6. Overall Inhaled and Intranasal Drug Delivery System Contract Manufacturing Market, 2020-2030
13. IMPACT OF COVID-19 PANDEMIC ON THE INHALED AND INTRANASAL SERVICE PROVIDERS MARKET
13.1 Chapter Overview
13.2. Current Opinions and Recuperative Initiatives of Key Players
13.2.1. Catalent
13.2.2. Hovione
13.2.3. Lonza
13.2.4. Quotient Sciences
13.2.5. Recipharm
13.3. Impact on Inhaled and Intranasal Product Service Providers Market
13.4. Recuperative Strategies for Contract Service Providers
13.4.1. Strategies for Implementation in the Short / Mid Term
13.4.2. Strategies for Implementation in the Long Term
14. CONCLUSION
14.1. Chapter Overview
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. King's College London
15.2.1. Organization Snapshot
15.2.2. Interview Transcript: Ben Forbes, Professor
15.3. Nelson Laboratories
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Dries Cardoen, Team Leader of Study Directors
15.4. The Indian Pharmaceutical Association
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Neeraj Kumar, Honorary Secretary
16. APPENDIX 1: TABULATED DATA
For more information about this report visit https://www.researchandmarkets.com/r/4i9ls6
These press releases may also interest you
|